Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice

An accumulating body of evidence demonstrates that radiation therapy can generate adaptive immune responses that contribute to tumor control. However, in the absence of additional immune therapy, the adaptive immune response is insufficient to prevent tumor recurrence or affect distant disease. It h...

Full description

Bibliographic Details
Main Authors: Crittenden, Marka R., Savage, Talicia, Cottam, Benjamin, Baird, Jason, Rodriguez, Paulo C., Newell, Pippa, Young, Kristina, Jackson, Andrew M., Gough, Michael J.
Format: Article
Published: Radiation Research Society 2014
Online Access:https://eprints.nottingham.ac.uk/33654/
_version_ 1848794674844663808
author Crittenden, Marka R.
Savage, Talicia
Cottam, Benjamin
Baird, Jason
Rodriguez, Paulo C.
Newell, Pippa
Young, Kristina
Jackson, Andrew M.
Gough, Michael J.
author_facet Crittenden, Marka R.
Savage, Talicia
Cottam, Benjamin
Baird, Jason
Rodriguez, Paulo C.
Newell, Pippa
Young, Kristina
Jackson, Andrew M.
Gough, Michael J.
author_sort Crittenden, Marka R.
building Nottingham Research Data Repository
collection Online Access
description An accumulating body of evidence demonstrates that radiation therapy can generate adaptive immune responses that contribute to tumor control. However, in the absence of additional immune therapy, the adaptive immune response is insufficient to prevent tumor recurrence or affect distant disease. It has been shown in multiple models that tumor-infiltrating myeloid cells exhibit alternative activation phenotypes and are able to suppress adaptive immune responses, and recent data suggests that the myeloid response in tumors treated with cytotoxic therapy limits tumor control. We hypothesized that tumor myeloid cells inhibit the adaptive immune response after radiation therapy through expression of the enzyme arginase I. Using a myeloid cell-specific deletion of arginase I in mice, we demonstrate an improved tumor control after radiation therapy. However, tumors still recurred despite the conditional knockdown of arginase I. Since multiple alternative factors may combine to inhibit adaptive immunity, we propose that targeting macrophage differentiation may be a more effective strategy than targeting individual suppressive pathways.
first_indexed 2025-11-14T19:19:57Z
format Article
id nottingham-33654
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:19:57Z
publishDate 2014
publisher Radiation Research Society
recordtype eprints
repository_type Digital Repository
spelling nottingham-336542020-05-04T16:49:59Z https://eprints.nottingham.ac.uk/33654/ Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice Crittenden, Marka R. Savage, Talicia Cottam, Benjamin Baird, Jason Rodriguez, Paulo C. Newell, Pippa Young, Kristina Jackson, Andrew M. Gough, Michael J. An accumulating body of evidence demonstrates that radiation therapy can generate adaptive immune responses that contribute to tumor control. However, in the absence of additional immune therapy, the adaptive immune response is insufficient to prevent tumor recurrence or affect distant disease. It has been shown in multiple models that tumor-infiltrating myeloid cells exhibit alternative activation phenotypes and are able to suppress adaptive immune responses, and recent data suggests that the myeloid response in tumors treated with cytotoxic therapy limits tumor control. We hypothesized that tumor myeloid cells inhibit the adaptive immune response after radiation therapy through expression of the enzyme arginase I. Using a myeloid cell-specific deletion of arginase I in mice, we demonstrate an improved tumor control after radiation therapy. However, tumors still recurred despite the conditional knockdown of arginase I. Since multiple alternative factors may combine to inhibit adaptive immunity, we propose that targeting macrophage differentiation may be a more effective strategy than targeting individual suppressive pathways. Radiation Research Society 2014-08-01 Article PeerReviewed Crittenden, Marka R., Savage, Talicia, Cottam, Benjamin, Baird, Jason, Rodriguez, Paulo C., Newell, Pippa, Young, Kristina, Jackson, Andrew M. and Gough, Michael J. (2014) Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice. Radiation Research, 182 (2). pp. 182-90. ISSN 1938-5404 http://www.bioone.org/doi/10.1667/RR13493.1 doi:10.1667/RR13493.1 doi:10.1667/RR13493.1
spellingShingle Crittenden, Marka R.
Savage, Talicia
Cottam, Benjamin
Baird, Jason
Rodriguez, Paulo C.
Newell, Pippa
Young, Kristina
Jackson, Andrew M.
Gough, Michael J.
Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice
title Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice
title_full Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice
title_fullStr Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice
title_full_unstemmed Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice
title_short Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice
title_sort expression of arginase i in myeloid cells limits control of residual disease after radiation therapy of tumors in mice
url https://eprints.nottingham.ac.uk/33654/
https://eprints.nottingham.ac.uk/33654/
https://eprints.nottingham.ac.uk/33654/